Similar articles

• Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.

  Spaepen K, Mortelmans L. Spaepen K, et al. Q J Nucl Med. 2001 Sep;45(3):269-73. Q J Nucl Med. 2001. PMID: 11788819 Review.
• FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma.

  Kasamon YL, Wahl RL. Kasamon YL, et al. Curr Opin Oncol. 2008 Mar;20(2):206-19. doi: 10.1097/CCO.0b013e3282f5123d. Curr Opin Oncol. 2008. PMID: 18300772 Free PMC article. Review.
• 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?

  Juweid ME. Juweid ME. J Nucl Med. 2008 Jan;49(1):9-12. doi: 10.2967/jnumed.107.046292. Epub 2007 Dec 12. J Nucl Med. 2008. PMID: 18077522 Review. No abstract available.
• Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.

  Nuutinen J, Minn H, Bergman J, Haaparanta M, Ruotasalainen U, Laine H, Knuuti J. Nuutinen J, et al. Br J Cancer. 1999 May;80(3-4):513-8. doi: 10.1038/sj.bjc.6690386. Br J Cancer. 1999. PMID: 10408861 Free PMC article.
• Evidence for a cardiac metabolic switch in patients with Hodgkin's lymphoma.

  Heckmann MB, Totakhel B, Finke D, Anker MS, Müller-Tidow C, Haberkorn U, Katus HA, Lehmann LH. Heckmann MB, et al. ESC Heart Fail. 2019 Aug;6(4):824-829. doi: 10.1002/ehf2.12475. Epub 2019 Jul 6. ESC Heart Fail. 2019. PMID: 31278857 Free PMC article.